Exenatide for the treatment of type 2 diabetes mellitus
Ruddock B
Record ID 32005001200
English, French
Authors' objectives:
The aim of this report is to summarize the available information on the use of exenatide as an add-on therapy for patients with type 2 diabetes mellitus who are taking oral antidiabetic drugs.
Authors' recommendations:
Evidence indicates that exenatide reduces glycosylated hemoglobin and plasma glucose levels when compared with placebo. Limitations of the therapy include the need for twice daily injections and potentially dose-limiting nausea and vomiting. Long-term studies are required to determine the effects of exenatide on disease related morbidity and mortality.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/publications/pdf/370_exenatide_cetap_e.pdf
Year Published:
2005
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Hypoglycemic Agents
- Diabetes Mellitus, Type 2
- Exenatide
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.